SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community anticipates further upside, with some eyeing previous highs and staking opportunities. Discussion is centered around potential rallies and the possibility of outperforming other major cryptocurrencies. Talk also highlights treasury strategies and corporate adoption as potential catalysts for growth.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle ($ORCL) is trending due to news of a significant cloud computing deal with OpenAI, sparking both excitement and skepticism within the community. Some investors believe the deal will propel ORCL to new heights, while others question the financial viability and sustainability of OpenAI's involvement and consider the surge a potential bubble. Community members are actively debating the long-term implications of the partnership, with some highlighting potential risks and an insider lock-up ending soon.

Why Queen Kitty ($QKitty) Is The Meme Token You’ve Been Waiting For  Queen Kitty isn’t just another hype project—this is a real movement with substance and community power!  Why hold $QKitty? 😼 Real dev, real builds: No fake teams, no copy-paste code. Everything you see is made from scratch. 💧 Working Faucet: Free QKitty for the community. Want to know how? Just ask! 🏆 Big Buy Competition Bot: See top buyers live, fight for the throne, and win rewards! 🎮 Multi-token P2E game coming soon: Play and earn across Web, iOS, Android! 🐾 NFT collecting soon: Cutest collection in crypto, bringing perks and more ways to earn.  Queen Kitty means innovation, transparency, and real delivery for holders. Curious? Join the chat and ask anything!  $QKitty: By the community, for the community. To the moon, together! 🚀🐱

Queen Kitty

Queen Kitty is trending amid discussions about its upcoming DEX launch in November and a trading bot that generates revenue. The community is also buzzing about a potential airdrop of QKITTY.X and BROKE.X tokens. Some users highlight that the project emphasizes transparency and has a trusted developer.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is trending downwards, driven by an analyst downgrade and concerns over increasing competition from Amazon and Netflix, leading to a significant sell-off. Community sentiment is largely negative, with many investors expressing frustration and questioning the company's leadership and strategic direction. Some investors believe the stock is oversold and ripe for a bounce, while others fear further declines and are considering exiting their positions.

Wearable Devices Ltd. engages in the development of a non-invasive neural input technology that allows operation and control of digital devices using subtle finger movements and fingertip pressure. It offers Mudra band, a neutral input wristband. The company was founded by Asher Dahan, Guy Wagner, and Leeor Langer in March 2014 and is headquartered in Yokne'am Illit, Israel.

Wearable Devices Ltd

WLDS is trending due to a recently granted U.S. patent for its gesture and voice-controlled interface technology, sparking discussions about potential applications in AI wearables and possible acquisition by major tech companies like Apple. The community is actively debating the stock's potential for a multi-day run, buyout speculation, and potential short squeeze, while also weighing concerns about possible dilution. Some traders are drawing comparisons to other high-flying stocks.

Klarna Group Plc operates as an investment holding company. It provides an e-commerce payment solutions for merchants and shoppers. The firm connect an array of different financial services and commerce organizations, from PSPs, traditional banks, card networks and open banking providers, to commerce enablers, technology partners, in-store payments providers and shipping and return logistics providers. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna's NYSE debut has traders discussing its valuation relative to competitors like Affirm, with some pointing to its potential for long-term growth in the BNPL sector. Concerns about the company's business model and potential regulatory scrutiny are also circulating. The IPO's initial price action and allocation sizes are driving immediate conversation within the community.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

AVXL is trending due to discussions surrounding its potential Alzheimer's drug and recent clinical data, with community members debating the efficacy and safety profile compared to existing treatments. Some traders are pointing to potential short squeezes and heavy manipulation, while others express concerns about the company's history and await EMA approval. The stock's volatile price movement is fueling speculation about its future.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending due to a special dividend announcement in the form of warrants, sparking debate about its implications. While some community members see this as a catalyst for a potential short squeeze and long-term value, others express concerns about potential dilution and market manipulation. The stock's volatile price action and heavy trading volume are fueling active discussions about its future direction and the impact of the warrant distribution.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending as investors debate its future amidst competition from companies like Klarna, with some seeing it as a value trap and others anticipating a rise due to buybacks and potential rate cuts. Community discussions revolve around the stock's inability to sustain gains and frustration with its performance compared to other fintech and tech stocks. Some analysts believe PayPal's value is suppressed and are waiting for a breakout.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid heated online discussions and political tensions, sparked by a shooting involving conservative figure Charlie Kirk and its connection to politically charged rhetoric. The community is actively debating gun control, political violence, and the role of inflammatory language in current events, with some users expressing extreme views and calling for violence. The situation unfolds against a backdrop of broader concerns about political polarization and its potential consequences.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Hims &amp; Hers Health, Inc. (HIMS) rose 3% on Wednesday after the telehealth company launched a new category in men’s health, offering access to innovative, affordable, and personalized treatment plans for low testosterone.The company estimates that over 20 million men in the U.S. struggle with low testosterone, but noted that most never receive care due to stigma, outdated treatments, and high costs.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> stayed within the ‘bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels. According to Stocktwits data, retail chatter around the stock increased by 21% over the last 24 hours and by approximately 533% over the last 30 days as of the early hours on Wednesday.<figure class="image"><img style="aspect-ratio:624/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_10_at_12_36_35_PM_png_dcb797f889.webp" alt="HIMS's Sentiment Meter and Message Volume as of 12:36 p.m. ET on Sept. 10, 2025 | Source: Stocktwits" width="624" height="61"><figcaption>HIMS' Sentiment Meter and Message Volume as of 12:36 p.m. ET on Sept. 10, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said that the stock continues to rally without offering a favorable entry point.<stembedurl>https://stocktwits.com/Canyonfundstrader2007/message/628171596</stembedurl>Hims <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.hims.com/news/news-details/2025/Hims-Launches-New-Category-in-Mens-Health-with-Exclusive-Branded-Oral-Testosterone-and-Expanded-Personalized-Treatments/default.aspx">said</a> on Wednesday that low testosterone, if left untreated, can drain energy, dull mood and sexual desire, and raise risks of heart disease, diabetes, and cancer. Starting in 2026, the company will launch a branded oral testosterone called Kyzatrex through a collaboration with Marius Pharmaceuticals. Kyzatrex is FDA-approved and has been shown to restore testosterone levels in up to 96% of men, Hims said.The company also stated that it will introduce access to injectable testosterone treatments in 2026. Providers will also be able to prescribe tailored doses of compounded Enclomiphene for men experiencing sexual symptoms through the Hims &amp; Hers platform starting Wednesday, the company said. Enclomiphene has been shown to double testosterone levels by restoring natural testosterone production, the company stated. Bloomberg <a href="https://stocktwits.com/news-articles/markets/equity/hims-and-hers-to-launch-low-testosterone-treatments-for-men-as-weight-loss-drug-sales-slow/chwjw9LRdt6">reported</a> that Hims will make the announcement earlier in the day.&nbsp;Separately, on Tuesday, the U.S. Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) announced a major reform of pharmaceutical advertisements, which will require drug companies to include full safety warnings in their direct-to-consumer ads.According to BofA analyst Allen Lutz, these industry changes are likely to make new customer conversions more challenging through ads, given the competitive pressures in the sexual health, hair loss, and weight loss sectors. Overall, Hims &amp; Hers should be able to navigate this environment given its strong brand equity and first-mover advantage, the analyst said, while adding that it would expect continued volatility in the near term.The firm kept an ‘Underperform’ rating on Hims &amp; Hers with a price target of $28 on the shares.HIMS stock has more than doubled in value this year and more than tripled over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/merck-reportedly-scraps-research-centre-in-uk/chwkKULRdut">Merck Reportedly Scraps Research Centre In UK: Retail Sees Stock Rallying To $97.50</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Hims & Hers Health, Inc. is displayed on a smartphone screen on May 04, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Hims & Hers Stock Rises After Company Launches Treatment Plans For Low Testosterone

According to Stocktwits data, retail chatter around HIMS stock increased by 21% over the last 24 hours and by approximately 533% over the last 30 days as of the early hours on Wednesday.

Equity

According to Stocktwits data, retail chatter around HIMS stock increased by 21% over the last 24 hours and by approximately 533% over the last 30 days as of the early hours on Wednesday.



Hims &amp; Hers Health will launch treatments for men with low testosterone on Wednesday, entering the fast-growing hormonal health segment as slowing weight-loss drug sales weigh on its stock.The telehealth company will start with a compounded version of enclomiphene, an off-label therapy for low testosterone. Pricing will vary by treatment cadence: a three-month plan costs approximately $199 per month, a five-month plan $139, and a 10-month plan $99, Bloomberg&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-10/hims-to-launch-new-offerings-for-men-with-low-testosterone">reported</a>, citing an internal document. The figures could still change.CEO Andrew Dudum&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/AndrewDudum/status/1965515395110142254">signaled the launch on X</a>, writing Tuesday: “T-minus 1 day until a new era at @wearehims.”Investors have been awaiting the move since Hims disclosed its plans earlier this year. While the initial rollout targets men, the company has said it intends to add hormonal therapies for women in perimenopause and menopause.Hims expanded into diagnostics with the February acquisition of an at-home lab testing firm, enabling easier testosterone testing. Lab services will also be offered as a standalone product.&nbsp;On an August call, Dudum said the company aims to address hormonal health issues affecting more than 50 million Americans that have long been overlooked by traditional care.On Stocktwits, retail sentiment for Hims was ‘bullish’ amid ‘normal’ message volume.<a href="https://stocktwits.com/symbol/HIMS">Hims &amp; Hers Health’s stock</a> has nearly doubled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Hims & Hers Health logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Hims & Hers To Launch Low Testosterone Treatments for Men As Weight-Loss Drug Sales Slow

The telehealth company is expanding into hormonal health with plans to eventually add therapies for women in perimenopause and menopause. 

Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note

In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $47.79, marking a -3.73% move from the previous day.

Hims & Hers Expanding Partnerships to Build a Global Health Ecosystem

HIMS expands its digital health footprint with global moves, top-tier partnerships and more than 1,500 providers.

Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock

Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

HIMS' Personalized Wellness Platform Expands Preventive Care Access

Hims & Hers expands its personalized wellness platform, aiming to reshape preventive care through tech-driven, holistic solutions.

HIMS vs. AMWL: Which Stock Has the Stronger Global Growth Strategy?

Hims & Hers expands globally, while Amwell leans on federal contracts and software growth. Let's see which has the edge in earnings growth & strategic expansion.

Hims & Hers Scales Growth Through Subscriptions and Care Expansion

HIMS fuels growth through subscriptions, expanding care offerings and building proprietary health infrastructure at scale.

Hims & Hers Fuels Growth via Market Expansion and New Care Verticals

HIMS eyes long-term growth with new hormonal health offerings, international expansion and high GLP-1 retention.

Levi & Korsinsky Notifies Shareholders of Hims & Hers Health, Inc.(HIMS) of a Class Action Lawsuit and an Upcoming Deadline

Levi & Korsinsky Notifies Shareholders of Hims & Hers Health, Inc.(HIMS) of a Class Action Lawsuit and an Upcoming Deadline Levi & Korsinsky Notifies Shareholders of Hims & Hers Health, Inc.(HIMS) of...

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Buying for a long-term investment

Buying for a short-term trade

Trading around the volatility

Avoiding it

$KLAR IPO day is upon us, how are you playing it?

Stocktwits

 IPO day is upon us, how are you playing it?

HIMS
Hims & Hers Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HIMS News

HIMS Hims & Hers Health Inc